These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 22195646)

  • 41. Update on the medical treatment of metastatic renal cell carcinoma.
    Ravaud A; Wallerand H; Culine S; Bernhard JC; Fergelot P; Bensalah K; Patard JJ
    Eur Urol; 2008 Aug; 54(2):315-25. PubMed ID: 18485581
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Use of biologics for psoriasis in Central and Eastern European countries.
    Rencz F; Kemény L; Gajdácsi JZ; Owczarek W; Arenberger P; Tiplica GS; Stanimirović A; Niewada M; Petrova G; Marinov LT; Kazandhieva J; Péntek M; Brodszky V; Gulácsi L
    J Eur Acad Dermatol Venereol; 2015 Nov; 29(11):2222-30. PubMed ID: 26370506
    [TBL] [Abstract][Full Text] [Related]  

  • 43. An international expanded-access programme of everolimus: addressing safety and efficacy in patients with metastatic renal cell carcinoma who progress after initial vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapy.
    Grünwald V; Karakiewicz PI; Bavbek SE; Miller K; Machiels JP; Lee SH; Larkin J; Bono P; Rha SY; Castellano D; Blank CU; Knox JJ; Hawkins R; Anak O; Rosamilia M; Booth J; Pirotta N; Bodrogi I;
    Eur J Cancer; 2012 Feb; 48(3):324-32. PubMed ID: 21803569
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Everolimus for the second-line treatment of advanced and/or metastatic renal cell cancer: a critique of the submission from Novartis.
    Pitt M; Crathorne L; Moxham T; Bond M; Hyde C
    Health Technol Assess; 2010 Oct; 14(Suppl. 2):41-6. PubMed ID: 21047490
    [TBL] [Abstract][Full Text] [Related]  

  • 45. New systemic treatment options for metastatic renal-cell carcinoma in the era of targeted therapies.
    Tan TH; Pranavan G; Haxhimolla HZ; Yip D
    Asia Pac J Clin Oncol; 2010 Mar; 6(1):5-18. PubMed ID: 20398033
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The therapy of kidney cancer with biomolecular drugs.
    Di Lorenzo G; Buonerba C; Biglietto M; Scognamiglio F; Chiurazzi B; Riccardi F; Cartenì G
    Cancer Treat Rev; 2010 Nov; 36 Suppl 3():S16-20. PubMed ID: 21129605
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Renal cell carcinoma therapy in 2010: many options with little comparative data.
    Pal SK; Figlin RA
    Clin Adv Hematol Oncol; 2010 Mar; 8(3):191-200. PubMed ID: 20400934
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Everolimus in metastatic renal cell carcinoma after failure of initial vascular endothelial growth factor receptor-tyrosine kinase inhibitor (VEGFr-TKI) therapy: results of an interim analysis of a non-interventional study.
    Bergmann L; Goebell PJ; Kube U; Kindler M; Herrmann E; Janssen J; Schmitz J; Weikert S; Steiner G; Jakob A; Staehler MD; Steiner T; Overkamp F; Albrecht M; Guderian G; Doehn C
    Onkologie; 2013; 36(3):95-100. PubMed ID: 23485996
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The impact of kidney function on the outcome of metastatic renal cell carcinoma patients treated with vascular endothelial growth factor-targeted therapy.
    Macfarlane R; Heng DY; Xie W; Knox JJ; McDermott DF; Rini BI; Kollmannsberger C; Choueiri TK
    Cancer; 2012 Jan; 118(2):365-70. PubMed ID: 21717427
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Eye healthcare services in eastern Europe: Part 1. Cataract surgery.
    Kocur I; Resnikoff S; Foster A;
    Br J Ophthalmol; 2002 Aug; 86(8):847-50. PubMed ID: 12140200
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Cancer Control in Central and Eastern Europe: Current Situation and Recommendations for Improvement.
    Vrdoljak E; Bodoky G; Jassem J; Popescu RA; Mardiak J; Pirker R; Čufer T; Bešlija S; Eniu A; Todorović V; Kubáčková K; Kurteva G; Tomašević Z; Sallaku A; Smichkoska S; Bajić Ž; Šikić BI
    Oncologist; 2016 Oct; 21(10):1183-1190. PubMed ID: 27401890
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Prognostic factors for cases with metastatic renal cell carcinoma in the era of targeted medicine.
    Neuzillet Y; Culine S; Patard JJ
    Int J Urol; 2009 Nov; 16(11):855-61. PubMed ID: 19674168
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Challenges and opportunities for converting renal cell carcinoma into a chronic disease with targeted therapies.
    Gore ME; Larkin JM
    Br J Cancer; 2011 Feb; 104(3):399-406. PubMed ID: 21285971
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Multidisciplinary management of metastatic renal cell carcinoma in the era of targeted therapies.
    Escudier B; Osanto S; Ljungberg B; Porta C; Wagstaff J; Mulders P; Gore M; Bex A; Bellmunt J; Bracarda S; Franklin A; Honoré PH; Ravaud A; Steijn Jv; Aziz Z; Akaza H
    Cancer Treat Rev; 2012 Apr; 38(2):127-32. PubMed ID: 21689888
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Oncolytic virotherapy for renal cell carcinoma: a novel treatment paradigm?
    Lawson KA; Morris DG
    Expert Opin Biol Ther; 2012 Jul; 12(7):891-903. PubMed ID: 22564154
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Metastatic renal cell carcinoma: recent advances in the targeted therapy era.
    Di Lorenzo G; Autorino R; Sternberg CN
    Eur Urol; 2009 Dec; 56(6):959-71. PubMed ID: 19748725
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Health technology assessment and reimbursement policy for oncology orphan drugs in Central and Eastern Europe.
    Malinowski KP; Kawalec P; Trąbka W; Sowada C; Petrova G; Manova M; Savova A; Draganić P; Slabý J; Männik A; Márky K; Rugaja Z; Gulbinovic J; Tesar T; Paveliu MS
    Orphanet J Rare Dis; 2020 Oct; 15(1):277. PubMed ID: 33032634
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Patient-based strategy for systemic treatment of metastatic renal cell carcinoma.
    Kirchner H; Strumberg D; Bahl A; Overkamp F
    Expert Rev Anticancer Ther; 2010 Apr; 10(4):585-96. PubMed ID: 20397923
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Treatment of metastatic renal cell carcinoma.
    Reeves DJ; Liu CY
    Cancer Chemother Pharmacol; 2009 Jun; 64(1):11-25. PubMed ID: 19343348
    [TBL] [Abstract][Full Text] [Related]  

  • 60. New targeted therapies for renal cell carcinoma.
    Fisher R; Pickering L; Larkin J
    Expert Opin Investig Drugs; 2011 Jul; 20(7):933-45. PubMed ID: 21506895
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.